{"id":"interferon-beta-1a-avonex","safety":{"commonSideEffects":[{"rate":"~60%","effect":"Flu-like symptoms (fever, chills, myalgia)"},{"rate":"~40%","effect":"Injection site reactions"},{"rate":"~30%","effect":"Headache"},{"rate":"~15%","effect":"Elevated liver enzymes"},{"rate":"~10%","effect":"Leukopenia"},{"rate":"~5%","effect":"Depression"}]},"_chembl":{"chemblId":"CHEMBL1201562","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon beta-1a binds to interferon-beta receptors on immune cells and other tissues, triggering JAK-STAT signaling and other downstream pathways that enhance antiviral and immunoregulatory responses. In multiple sclerosis, this leads to reduced T-cell proliferation, decreased pro-inflammatory cytokine production, and reduced migration of immune cells across the blood-brain barrier, thereby slowing disease progression and reducing relapse rates.","oneSentence":"Interferon beta-1a activates interferon signaling pathways to modulate immune responses and reduce inflammatory activity in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:19.301Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"},{"name":"Secondary progressive multiple sclerosis with active disease"}]},"trialDetails":[{"nctId":"NCT06053749","phase":"","title":"An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-03-20","conditions":"Multiple Sclerosis (MS)","enrollment":4},{"nctId":"NCT04788615","phase":"PHASE3","title":"Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-23","conditions":"Multiple Sclerosis","enrollment":185},{"nctId":"NCT01892722","phase":"PHASE3","title":"Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2013-07-26","conditions":"Multiple Sclerosis","enrollment":240},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT03958877","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2019-10-18","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":152},{"nctId":"NCT03535298","phase":"PHASE4","title":"Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2019-01-03","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":800},{"nctId":"NCT05658497","phase":"","title":"Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)","status":"RECRUITING","sponsor":"Biogen","startDate":"2023-10-27","conditions":"Multiple Sclerosis","enrollment":908},{"nctId":"NCT02283853","phase":"PHASE3","title":"Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-08-28","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":156},{"nctId":"NCT06812585","phase":"PHASE2","title":"The Effect of Metformin As an Adjuvant Therapy on Immunological Parameters in Egyptian Patients with RRMS: a Pilot Study","status":"COMPLETED","sponsor":"German University in Cairo","startDate":"2022-04-01","conditions":"Multiple Sclerosis (MS) - Relapsing-remitting","enrollment":30},{"nctId":"NCT00676715","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-07-17","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":220},{"nctId":"NCT04315948","phase":"PHASE3","title":"Trial of Treatments for COVID-19 in Hospitalized Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2020-03-22","conditions":"Corona Virus Infection","enrollment":1552},{"nctId":"NCT03283397","phase":"PHASE3","title":"A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS","status":"TERMINATED","sponsor":"Bosnalijek D.D","startDate":"2019-03-26","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":301},{"nctId":"NCT06510426","phase":"PHASE2","title":"Early Interferon-beta Treatment for West-Nile Virus Infection","status":"RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2024-07-14","conditions":"West Nile Virus, West Nile Fever Encephalitis, West Nile Fever Myelitis","enrollment":100},{"nctId":"NCT05936229","phase":"PHASE1, PHASE2","title":"Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-04-01","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia","enrollment":""},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT00771043","phase":"PHASE4","title":"A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a","status":"WITHDRAWN","sponsor":"Biogen","startDate":"2008-11-01","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":""},{"nctId":"NCT06019130","phase":"PHASE2","title":"Nivolumab in Children and Adults With Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"German Society for Pediatric Oncology and Hematology GPOH gGmbH","startDate":"2023-01-10","conditions":"Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharyngeal Neoplasms","enrollment":57},{"nctId":"NCT04183491","phase":"PHASE1","title":"Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2020-02-28","conditions":"Healthy Subjects, Pharmacokinetics, Pharmacodynamics","enrollment":84},{"nctId":"NCT01412333","phase":"PHASE3","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09-20","conditions":"Relapsing Multiple Sclerosis","enrollment":835},{"nctId":"NCT01247324","phase":"PHASE3","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-08-31","conditions":"Relapsing Multiple Sclerosis","enrollment":821},{"nctId":"NCT05735067","phase":"","title":"The Impact of Body Weight on Clinical and Immunological Outcomes in Relapse-Remitting Multiple Sclerosis Patients","status":"UNKNOWN","sponsor":"German University in Cairo","startDate":"2022-02-01","conditions":"Multiple Sclerosis","enrollment":138},{"nctId":"NCT02587065","phase":"PHASE4","title":"Plegridy Satisfaction Study in Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2016-02-03","conditions":"Relapsing-Remitting Multiple Sclerosis (RRMS)","enrollment":193},{"nctId":"NCT04860518","phase":"PHASE2","title":"Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19","status":"TERMINATED","sponsor":"Faron Pharmaceuticals Ltd","startDate":"2021-08-23","conditions":"Covid19","enrollment":7},{"nctId":"NCT04079088","phase":"PHASE2","title":"Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)","status":"WITHDRAWN","sponsor":"Biogen","startDate":"2021-06-30","conditions":"Relapsing Multiple Sclerosis","enrollment":""},{"nctId":"NCT04314817","phase":"","title":"Adverse Events Related to Treatments Used Against Coronavirus Disease 2019","status":"COMPLETED","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2020-03-17","conditions":"Coronavirus, Iatrogenic Disease, Acute Kidney Injury","enrollment":1000},{"nctId":"NCT04655222","phase":"","title":"Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program","status":"COMPLETED","sponsor":"Biogen","startDate":"2021-04-30","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":470},{"nctId":"NCT02937285","phase":"PHASE3","title":"National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2010-12-06","conditions":"Multiple Sclerosis","enrollment":35},{"nctId":"NCT05298670","phase":"PHASE2","title":"Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients","status":"UNKNOWN","sponsor":"German University in Cairo","startDate":"2022-02-01","conditions":"Multiple Sclerosis","enrollment":80},{"nctId":"NCT02727907","phase":"PHASE2, PHASE3","title":"Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Biocad","startDate":"2015-02-12","conditions":"Multiple Sclerosis","enrollment":163},{"nctId":"NCT03570359","phase":"PHASE2","title":"A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza","status":"COMPLETED","sponsor":"Synairgen Research Ltd.","startDate":"2018-01-29","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":122},{"nctId":"NCT00246324","phase":"PHASE4","title":"Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis","status":"COMPLETED","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2003-12","conditions":"Multiple Sclerosis","enrollment":16},{"nctId":"NCT05242133","phase":"PHASE3","title":"Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2017-12-20","conditions":"Relapsing Remitting Multiple Sclerosis (RRMS)","enrollment":168},{"nctId":"NCT02230969","phase":"","title":"Plegridy Observational Program","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-11-12","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":1208},{"nctId":"NCT04834401","phase":"","title":"Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis","status":"COMPLETED","sponsor":"St. Barnabas Medical Center","startDate":"2021-03-22","conditions":"Multiple Sclerosis, Covid19","enrollment":45},{"nctId":"NCT00605215","phase":"PHASE3","title":"BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2008-04-24","conditions":"Multiple Sclerosis","enrollment":1331},{"nctId":"NCT02921035","phase":"","title":"Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2016-06-30","conditions":"Relapsing Multiple Sclerosis (RMS)","enrollment":594},{"nctId":"NCT04492475","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 3 (ACTT-3)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-05","conditions":"COVID-19","enrollment":969},{"nctId":"NCT05024006","phase":"NA","title":"Public Health Emergency: SOLIDARITY TRIAL Philippines","status":"COMPLETED","sponsor":"University of the Philippines","startDate":"2020-04-23","conditions":"Covid19","enrollment":1314},{"nctId":"NCT01975298","phase":"PHASE3","title":"A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)","status":"WITHDRAWN","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-01","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":""},{"nctId":"NCT02744222","phase":"PHASE2, PHASE3","title":"Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Biocad","startDate":"2017-08-10","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":399},{"nctId":"NCT04032171","phase":"PHASE3","title":"Study of Evobrutinib in Participants With RMS","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-09-10","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":1},{"nctId":"NCT04032158","phase":"PHASE3","title":"Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-08-26","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":3},{"nctId":"NCT04647669","phase":"PHASE3","title":"World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments","status":"UNKNOWN","sponsor":"The University of The West Indies","startDate":"2021-06-01","conditions":"Covid19","enrollment":100},{"nctId":"NCT00725985","phase":"PHASE3","title":"Oral Cladribine in Early Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2008-12-31","conditions":"Multiple Sclerosis","enrollment":617},{"nctId":"NCT02047734","phase":"PHASE3","title":"Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Celgene","startDate":"2013-12-03","conditions":"Relapsing Multiple Sclerosis","enrollment":1320},{"nctId":"NCT03119701","phase":"PHASE2","title":"Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA","status":"TERMINATED","sponsor":"Faron Pharmaceuticals Ltd","startDate":"2017-02-18","conditions":"Preventive Medicine, Multi Organ Failure","enrollment":40},{"nctId":"NCT01623596","phase":"PHASE4","title":"Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06-08","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":881},{"nctId":"NCT00986960","phase":"PHASE2","title":"Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)","status":"WITHDRAWN","sponsor":"University at Buffalo","startDate":"2009-12","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT00463710","phase":"","title":"Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2005-06","conditions":"Multiple Sclerosis","enrollment":150},{"nctId":"NCT02294058","phase":"PHASE3","title":"Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Celgene","startDate":"2014-12-03","conditions":"Multiple Sclerosis","enrollment":1346},{"nctId":"NCT03177083","phase":"PHASE4","title":"Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-01-30","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":80},{"nctId":"NCT00436826","phase":"PHASE2","title":"A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2006-11-30","conditions":"Multiple Sclerosis","enrollment":172},{"nctId":"NCT04545372","phase":"NA","title":"Aerobic Exercises for Multiple Sclerosis","status":"COMPLETED","sponsor":"South Valley University","startDate":"2015-02-02","conditions":"Multiple Sclerosis, Primary Progressive","enrollment":30},{"nctId":"NCT04521400","phase":"PHASE2","title":"the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-08-20","conditions":"Covid19","enrollment":100},{"nctId":"NCT00273364","phase":"PHASE2","title":"Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-11-16","conditions":"Multiple Sclerosis","enrollment":110},{"nctId":"NCT04460547","phase":"","title":"Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic","status":"UNKNOWN","sponsor":"Qassim University","startDate":"2020-07-25","conditions":"COVID-19","enrollment":200},{"nctId":"NCT04343768","phase":"PHASE2","title":"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-04-09","conditions":"COVID-19","enrollment":60},{"nctId":"NCT04350671","phase":"PHASE4","title":"Interferon Beta 1a in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-04-15","conditions":"COVID-19","enrollment":40},{"nctId":"NCT04350684","phase":"PHASE4","title":"Umifenovir in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-04-15","conditions":"COVID-19","enrollment":40},{"nctId":"NCT02622724","phase":"PHASE3","title":"Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)","status":"TERMINATED","sponsor":"Faron Pharmaceuticals Ltd","startDate":"2015-12-23","conditions":"Respiratory Distress Syndrome, Adult","enrollment":301},{"nctId":"NCT04289675","phase":"","title":"Multiple Sclerosis: Chi3L1 and Treatment Efficacy","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2012-01-01","conditions":"Multiple Sclerosis","enrollment":63},{"nctId":"NCT03387046","phase":"PHASE2","title":"A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-03-26","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":7},{"nctId":"NCT03614715","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2017-11-27","conditions":"Bioequivalence, Healthy","enrollment":40},{"nctId":"NCT03347370","phase":"","title":"A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-11-27","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":626},{"nctId":"NCT03424733","phase":"PHASE4","title":"Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects","status":"UNKNOWN","sponsor":"Holy Name Medical Center, Inc.","startDate":"2017-09-25","conditions":"Multiple Sclerosis","enrollment":50},{"nctId":"NCT02749396","phase":"","title":"EPID Multiple Sclerosis Pregnancy Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-05-02","conditions":"Multiple Sclerosis","enrollment":2089},{"nctId":"NCT02491684","phase":"PHASE2","title":"A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07-21","conditions":"Asthma","enrollment":121},{"nctId":"NCT01514370","phase":"PHASE2","title":"Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2012-04-30","conditions":"Multiple Sclerosis","enrollment":80},{"nctId":"NCT02949908","phase":"","title":"MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2017-02-09","conditions":"Multiple Sclerosis","enrollment":2},{"nctId":"NCT02064816","phase":"PHASE4","title":"A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2014-05-31","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":200},{"nctId":"NCT03284970","phase":"","title":"Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2017-08-23","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":34},{"nctId":"NCT00078338","phase":"PHASE4","title":"Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2004-02-16","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":764},{"nctId":"NCT00037102","phase":"PHASE4","title":"Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis","status":"COMPLETED","sponsor":"MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute","startDate":"2001-07","conditions":"Multiple Sclerosis","enrollment":16},{"nctId":"NCT00037115","phase":"PHASE4","title":"Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.","status":"WITHDRAWN","sponsor":"MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute","startDate":"2002-05","conditions":"Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis","enrollment":""},{"nctId":"NCT01834586","phase":"PHASE4","title":"Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications","status":"COMPLETED","sponsor":"Brown, Theodore R., M.D., MPH","startDate":"2013-03","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT02254304","phase":"PHASE4","title":"Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2014-12-31","conditions":"Relapsing Multiple Sclerosis, Clinically Isolated Syndrome","enrollment":106},{"nctId":"NCT02823951","phase":"","title":"Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®","status":"COMPLETED","sponsor":"IMS HEALTH GmbH & Co. OHG","startDate":"2016-02","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":479},{"nctId":"NCT01085318","phase":"PHASE4","title":"Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2010-06-30","conditions":"Multiple Sclerosis","enrollment":38},{"nctId":"NCT01198132","phase":"PHASE2","title":"A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-11","conditions":"Multiple Sclerosis","enrollment":129},{"nctId":"NCT01119677","phase":"PHASE1","title":"A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-05-05","conditions":"Healthy Volunteers","enrollment":120},{"nctId":"NCT00340834","phase":"PHASE3","title":"Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-05","conditions":"Multiple Sclerosis","enrollment":1292},{"nctId":"NCT00179478","phase":"PHASE4","title":"Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2001-02","conditions":"Multiple Sclerosis, Optic Neuritis, Transverse Myelitis","enrollment":155},{"nctId":"NCT01791244","phase":"PHASE4","title":"A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2013-02-28","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":93},{"nctId":"NCT00097318","phase":"PHASE1","title":"Safety Study of Interferon Beta 1a to for Acute Stroke","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2004-11-17","conditions":"Cerebrovascular Accident","enrollment":60},{"nctId":"NCT02377323","phase":"NA","title":"Real-Life Outcomes of Multiple Sclerosis Treatment With Rebif","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2014-01","conditions":"Multiple Sclerosis","enrollment":296},{"nctId":"NCT00930553","phase":"PHASE3","title":"An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2009-08","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":1314},{"nctId":"NCT01864148","phase":"PHASE2","title":"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-08","conditions":"Multiple Sclerosis","enrollment":419},{"nctId":"NCT01049451","phase":"PHASE1","title":"Pulse ACTH vs. MP for MS","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2009-11","conditions":"Multiple Sclerosis","enrollment":23},{"nctId":"NCT00548405","phase":"PHASE3","title":"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-10","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":840},{"nctId":"NCT02359877","phase":"PHASE1","title":"Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2014-07","conditions":"Healthy","enrollment":60},{"nctId":"NCT00813709","phase":"PHASE3","title":"Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-12","conditions":"Multiple Sclerosis, Clinically Isolated Syndrome","enrollment":402},{"nctId":"NCT02019550","phase":"PHASE4","title":"Rebif® Rebidose® Versus Rebiject II® Ease-of-Use","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2014-03","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":97},{"nctId":"NCT02076841","phase":"","title":"Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-07","conditions":"Relapsing-Remitting Multiple Sclerosis, Clinical Isolated Syndrome (CIS), Multiple Sclerosis","enrollment":40},{"nctId":"NCT01939002","phase":"PHASE3","title":"Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-11","conditions":"Relapsing Multiple Sclerosis","enrollment":251},{"nctId":"NCT02117050","phase":"PHASE4","title":"RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate","status":"TERMINATED","sponsor":"EMD Serono","startDate":"2014-06","conditions":"Multiple Sclerosis","enrollment":1},{"nctId":"NCT01332019","phase":"PHASE3","title":"Long-Term Safety and Efficacy Study of Peginterferon Beta-1a","status":"COMPLETED","sponsor":"Biogen","startDate":"2011-04","conditions":"Relapsing Multiple Sclerosis","enrollment":1077},{"nctId":"NCT01285401","phase":"PHASE2","title":"Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-02","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":260},{"nctId":"NCT01717664","phase":"PHASE2","title":"Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2013-06","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":18},{"nctId":"NCT01064401","phase":"PHASE3","title":"Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-05","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":1841},{"nctId":"NCT00883337","phase":"PHASE3","title":"A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-04","conditions":"Multiple Sclerosis","enrollment":324}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABDOMINAL DISTENSION"},{"count":1,"reaction":"ALOPECIA"},{"count":1,"reaction":"BACK PAIN"},{"count":1,"reaction":"BLOOD PRESSURE DECREASED"},{"count":1,"reaction":"CHEST PAIN"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"EAR PAIN"},{"count":1,"reaction":"FEELING ABNORMAL"},{"count":1,"reaction":"FLUSHING"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avonex"],"phase":"marketed","status":"active","brandName":"Interferon beta-1a (Avonex)","genericName":"Interferon beta-1a (Avonex)","companyName":"Biogen","companyId":"biogen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interferon beta-1a activates interferon signaling pathways to modulate immune responses and reduce inflammatory activity in the central nervous system. Used for Relapsing-remitting multiple sclerosis, Secondary progressive multiple sclerosis with active disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}